Exclusives

MolecuLight announced that their flagship wound imaging device, MolecuLightDX, now integrates with the Intellicure EHR platform for seamless data and image transfer. The integrated platforms allow clinicians to optimize their workflow and...

Pensar announced a partnership with Centurion Therapeutics to distribute the Microdoc sNPWT device. Centurion Therapeutics is an organization focused on wound care led by a management team of former Orthofix employees. They are the exclusive...

ChartPath and WoundZoom announced a strategic partnership to enhance wound care management in long-term and post-acute care by combining ChartPath's user-friendly EHR platform with WoundZoom's advanced wound care technology.

RedDress announced that ActiGraft Pro demonstrated exceptional efficacy in facilitating healing for chronic neuropathic DFUs. ActiGraft Pro showed significant superiority, with 2.73 greater odds of reaching complete wound closure by week 12...

A 216-patient RCT will evaluate the efficacy and safety of ExcharEX in the debridement of VLUs with the primary outcome of complete debridement at 2 weeks and complete wound closure at 12 weeks. Not yet recruiting; with estimated study...

BioStem has registered a 60-patient study to evaluate the safety and efficacy of human placental allograft BR-AM (Vendaje) + SoC vs SoC only in the treatment of DFUs. Primary outcome measures 100% re-epithelialization over a 12-week period....

A 124-patient RCT will investigate the efficacy of single-layer amniotic membrane (XWRAP) and SoC vs. SoC alone for closure of non-healing DFUs with the primary outcome of percent of wound closure in 12 weeks. Not yet recruiting; estimated...

Stability Biologics initiated a 324-patient study to evaluate AmnioCore, Amnio Quad-Core + SoC vs SoC alone in management of DFU and VLU. Primary outcome measures the proportion of pts achieving complete closure at 1-12 weeks. Estimated study...

Coloplast shared that a new RCT comparing the performance of Kerecis fish skin to the standard of care in the treatment of complex DFUs is pending publication. This is the largest Kerecis study to date, with a sample size of more than 250...